AJR Am J Roentgenol
- MARGOLIS DJA, Chatterjee A, deSouza NM, Fedorov A, et al 
 Quantitative Prostate MRI, From the AJR Special Series on Quantitative Imaging.
 AJR Am J Roentgenol. 2024 Oct 2. doi: 10.2214/AJR.24.31715.
 
 
 BJU Int
 
 
- DAUNGSUPAWONG H, Wiwanitkit V 
 Comment on 'Socioeconomic disparities in prostate cancer screening: the impact of 
the Area Deprivation Index on PSA screening frequency'.
 BJU Int. 2025 Sep 4. doi: 10.1111/bju.16922.
 
 
- VLAMING M, Koole W, van Moorselaar RJA, Bleiker EMA, et al 
 Prevalence of germline pathogenic variants in 779 patients with metastatic 
prostate cancer.
 BJU Int. 2025 Sep 2. doi: 10.1111/bju.16916.
 
 
- BERTINI A, Cirulli GO, Stephens A, Finocchiaro A, et al 
 Reply to 'Comment on Bertini et al.: area deprivation and PSA screening 
disparities' and 'Comment on socioeconomic disparities in prostate cancer 
screening: the impact of the Area Deprivation Index on PSA screening frequency'.
 BJU Int. 2025 Sep 4. doi: 10.1111/bju.16924.
 
 
- ROBERTS IA, Cumberbatch MG, Catto JWF 
 Renal, bladder and prostate cancer surgery outcomes with respect to team 
familiarity.
 BJU Int. 2025 Sep 4. doi: 10.1111/bju.16920.
 
 
 BMC Urol
 
 
- LUDECKE J, Mohr MN, Schneider TR, Voss JW, et al 
 Combined robot-assisted surgery of upper and lower genitourinary tract with 
excellent early functional and oncological outcome - a case report of a 
concomitant nerve-sparing radical prostatectomy, diverticulectomy and 
ureterectomy.
 BMC Urol. 2025;25:225.
 
 
- AGUILA-GIMENO O, Jareno-Vicens A, Recasens CT 
 Pelvic floor rehabilitation before radical prostatectomy: a systematic review.
 BMC Urol. 2025;25:224.
 
 
 Br J Cancer
 
 
- HUANG H, Benzonana LL, Zhao H, Watts HR, et al 
 Correction to: Prostate cancer cell malignancy via modulation of HIF-1alpha pathway 
with isoflurane and propofol alone and in combination.
 Br J Cancer. 2025 Sep 5. doi: 10.1038/s41416-025-03175.
 
 
 Cancer
 
 
- NGUYEN DD, Satkunasivam R, Aminoltejari K, Hird A, et al 
 Association of patient and physician characteristics with 
androgen-deprivation-therapy intensification in patients with de novo 
hormone-sensitive metastatic prostate cancer: A population-based study.
 Cancer. 2025;131:e70070.
 
 
- NIERENGARTEN MB 
 Outcomes show a reduction in treatment failure associated with dose-escalated, 
hypofractionated radiation therapy for localized prostate cancer.
 Cancer. 2025;131:e70013.
 
 
- NIERENGARTEN MB 
 A persistent PSA level following radical prostatectomy for prostate cancer is 
associated with a worse prognosis.
 Cancer. 2025;131:e70012.
 
 
 Cancer Res
 
 
- JIANG J, Liu S, Xu C, He L, et al 
 LHX2 Rewires the Metabolic and Epigenetic Landscape to Drive Tumor Progression in 
Prostate Cancer.
 Cancer Res. 2025 Sep 3. doi: 10.1158/0008-5472.CAN-25-0587.
 
 
- MURPHY KC, DeMarco KD, Zhou L, Peura J, et al 
 MYC and p53 Alterations Cooperate through VEGF Signaling to Repress Cytotoxic T 
Cell and Immunotherapy Responses in Prostate Cancer.
 Cancer Res. 2025 Sep 3. doi: 10.1158/0008-5472.CAN-25-2532.
 
 
- LIU S, Hsu EC, Aslan M, Garcia-Marques F, et al 
 Extracellular Domain Shedding of TROP2 Activates EGFR Signaling to Drive Prostate 
Cancer Metastasis.
 Cancer Res. 2025 Sep 5. doi: 10.1158/0008-5472.CAN-24-4855.
 
 
 Eur J Radiol
 
 
- AGHAKHANYAN G, Barucci A, Pascali MA, Assante M, et al 
 NAVIGATOR: A regional multimodal imaging biobank initiative powered by AI tools 
for precision medicine in oncology.
 Eur J Radiol. 2025;191:112327.
 
 
- CURIA B, Bortolotto C, Brizzi L, Santagostini S, et al 
 Impact on MRI technologist of a PI-QUAL v2 educational program on prostate MRI 
image quality assessment.
 Eur J Radiol. 2025;191:112280.
 
 
- NATALI T, Kurucz LM, Fusaglia M, Mertens LS, et al 
 Automatic prostate volume estimation in transabdominal ultrasound images.
 Eur J Radiol. 2025;191:112274.
 
 
- BRENDER JR, Ota M, Nguyen N, Ford JW, et al 
 Predicting ADC map quality from T2-weighted MRI: A deep learning approach for 
early quality assessment to assist point-of-care.
 Eur J Radiol. 2025;191:112317.
 
 
 Int J Urol
 
 
- KAWASE M 
 Editorial Comment Regarding "Shifts in Diagnostic Approaches for Prostate Cancer: 
Impact of MRI-Informed Biopsies on Low-Risk Cancer Detection".
 Int J Urol. 2025 Sep 1. doi: 10.1111/iju.70218.
 
 
- MATSUYAMA N, Suzuki K, Tobe T, Ueki H, et al 
 Time to Oligoprogression From the Initiation of the Most Recent Systemic 
Treatment Is Associated With the Outcome of Progressive Site-Directed Therapy for 
Castration-Resistant Prostate Cancer.
 Int J Urol. 2025 Sep 2. doi: 10.1111/iju.70217.
 
 
- SUZUKI K, Hirata J, Ueki H, Wakita N, et al 
 Nomogram for Predicting the Survival Outcome of Cabazitaxel Treatment in Patients 
With Metastatic Castration-Resistant Prostate Cancer: A Multi-Institutional 
Analysis.
 Int J Urol. 2025 Sep 3. doi: 10.1111/iju.70219.
 
 
 J Magn Reson Imaging
 
 
- LIU BC, Ding XH, Xu HH, Bai X, et al 
 Preoperative Assessment of Extraprostatic Extension in Prostate Cancer Using an 
Interpretable Tabular Prior-Data Fitted Network-Based Radiomics Model From MRI.
 J Magn Reson Imaging. 2025 Sep 5. doi: 10.1002/jmri.70111.
 
 
 J Urol
 
 
- CHEN DC, Alhamdani Z, Papa N, Shen E, et al 
 The Blind Spot of PSMA-PET Staging? Intraductal Carcinoma of the Prostate Is 
Overrepresented in Patients With No Uptake Pattern on Prostate-Specific Membrane 
Antigen Positron Emission Tomography and High-Grade Prostate Cancer.
 J Urol. 2025 Sep 5:101097JU0000000000004734. doi: 10.1097/JU.0000000000004734.
 
 
 Lancet Oncol
 
 
- NIAZI T, Saad F, Tisseverasinghe S, Koul R, et al 
 Metastases-directed therapy in addition to standard systemic therapy in 
oligometastatic castration-resistant prostate cancer in Canada (GROUQ-PCS 9): a 
multicentre, open-label, randomised, phase 2 trial.
 Lancet Oncol. 2025;26:1158-1167.
 
 
 Nat Rev Urol
 
 
- FEIJO M, Carvalho TMA, Fonseca LRS, Vaz CV, et al 
 Endocrine-disrupting chemicals as prostate carcinogens.
 Nat Rev Urol. 2025;22:609-631.
 
 
 Oncogene
 
 
- CIVENNI G, Sandrini G, Merulla J, Musumeci C, et al 
 Integrated control of cancer stemness by sigma(1) receptor in advanced prostate 
cancer.
 Oncogene. 2025 Sep 2. doi: 10.1038/s41388-025-03541.
 
 
- RAZA M, Rajan AR, Kennedy BB, Reznicek TE, et al 
 ECD, a novel androgen receptor target promotes prostate cancer tumorigenesis by 
regulating glycolysis.
 Oncogene. 2025 Sep 4. doi: 10.1038/s41388-025-03559.
 
 
 Pol J Radiol
 
 
- SARA HI, Aydin H, Hizli F 
 The use of ADC histogram analysis in the diagnosis and determination of 
aggressiveness of peripheral zone prostate cancer.
 Pol J Radiol. 2025;90:e374-e383.
 
 
 Prostate
 
 
- YUKIHIRO K, Sekino Y, Kobayashi G, Hatayama T, et al 
 Comprehensive Analysis of Fraction of Genome Altered in Prostate Cancer 
Treatment.
 Prostate. 2025 Sep 1. doi: 10.1002/pros.70042.
 
 
- MARTINEZ OSORIO CA, Sopena Sutil R, Vilaseca Cabo A, Linares Espinos E, et al 
 Prostate-Specific Antigen Response at Six Months Predicts Progression in 
Metastatic Hormone-Sensitive Prostate Cancer Treated With Apalutamide.
 Prostate. 2025 Sep 4. doi: 10.1002/pros.70040.
 
 
 
Free Medical Abstracts
 Privacy Policy
Privacy Policy
 Sponsors
Sponsors
 Share
Share
© Amedeo 1997-2016